Literature DB >> 24527834

Inhibition of farnesyl pyrophosphate synthase prevents angiotensin II-induced cardiac fibrosis in vitro.

Z Li1, X Bi, M Wang, J Zhang, J Song, X Shen, J Han, G Fu, Y Ye.   

Abstract

Farnesyl pyrophosphate synthase (FPPS)-catalysed isoprenoid intermediates are important for the activation of Ras homologue gene family, member A (RhoA) in angiotensin (Ang) II-induced cardiac fibrosis. This study was designed to investigate the specific role of FPPS in the development of cardiac fibrosis. We demonstrated that FPPS expression was elevated in both in-vivo and in-vitro models of Ang II-mediated cardiac fibrosis. FPPS inhibition by zolendronate and FPPS knock-down by a silencing lentivirus decreased the expression of cardiac fibrosis marker genes, including collagen I, collagen III and transforming growth factor (TGF)-β1. FPPS inhibition was reversed by geranylgeraniol (GGOH) and mimicked by RhoA knock-down with siRhoA. The antagonistic effect of GGOH on the zolendronate-mediated modulation of RhoA activation in Ang II-stimulated cardiac fibroblasts was demonstrated by a pull-down assay. Furthermore, FPPS knock-down also prevented RhoA activation by Ang II in vitro. In conclusion, FPPS and RhoA may be part of a signalling pathway that plays an important role in Ang II-induced cardiac fibrosis in vitro.
© 2014 British Society for Immunology.

Entities:  

Keywords:  RhoA; cardiac fibrosis; farnesyl pyrophosphate synthase

Mesh:

Substances:

Year:  2014        PMID: 24527834      PMCID: PMC4008988          DOI: 10.1111/cei.12282

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

Review 1.  Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation.

Authors:  Andrew Leask
Journal:  Circ Res       Date:  2010-06-11       Impact factor: 17.367

2.  Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation.

Authors:  Oliver Adam; Daniel Lavall; Katharina Theobald; Mathias Hohl; Markus Grube; Sabine Ameling; Mark A Sussman; Stephan Rosenkranz; Heyo K Kroemer; Hans-Joachim Schäfers; Michael Böhm; Ulrich Laufs
Journal:  J Am Coll Cardiol       Date:  2010-02-02       Impact factor: 24.094

3.  Allicin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways.

Authors:  Chen Liu; Feng Cao; Qi-Zhu Tang; Ling Yan; Yu-Gang Dong; Li-Hua Zhu; Lang Wang; Zhou-Yan Bian; Hongliang Li
Journal:  J Nutr Biochem       Date:  2010-02-25       Impact factor: 6.048

4.  Rac1 and RhoA differentially regulate angiotensinogen gene expression in stretched cardiac fibroblasts.

Authors:  Suresh K Verma; Hind Lal; Honey B Golden; Fnu Gerilechaogetu; Manuela Smith; Rakeshwar S Guleria; Donald M Foster; Guangrong Lu; David E Dostal
Journal:  Cardiovasc Res       Date:  2010-12-03       Impact factor: 10.787

5.  Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy.

Authors:  Yang Ye; Yun Mou; Baobao Bai; Liang Li; Guo-Ping Chen; Shen-Jiang Hu
Journal:  Int J Biochem Cell Biol       Date:  2010-09-25       Impact factor: 5.085

6.  Rad GTPase inhibits cardiac fibrosis through connective tissue growth factor.

Authors:  Ji Zhang; Lin Chang; Chunlei Chen; Meiling Zhang; Yan Luo; Milton Hamblin; Luis Villacorta; Jing-Wei Xiong; Y Eugene Chen; Jifeng Zhang; Xiaojun Zhu
Journal:  Cardiovasc Res       Date:  2011-03-07       Impact factor: 10.787

7.  Chronic inhibition of farnesyl pyrophosphate synthase improves endothelial function in spontaneously hypertensive rats.

Authors:  Guo-Ping Chen; Liang Li; Yin Yang; Michael Fu; Lei Yao; Tao Wu; Xiao-Qin Zhang; Shen-Jiang Hu
Journal:  Biochem Pharmacol       Date:  2010-09-09       Impact factor: 5.858

8.  Real-time NMR study of guanine nucleotide exchange and activation of RhoA by PDZ-RhoGEF.

Authors:  Geneviève M C Gasmi-Seabrook; Christopher B Marshall; Melissa Cheung; Bryan Kim; Feng Wang; Ying Ju Jang; Tak W Mak; Vuk Stambolic; Mitsuhiko Ikura
Journal:  J Biol Chem       Date:  2009-12-17       Impact factor: 5.157

9.  Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats.

Authors:  Liang Li; Guo-Ping Chen; Yin Yang; Yang Ye; Lei Yao; Shen-Jiang Hu
Journal:  Biochem Pharmacol       Date:  2009-10-02       Impact factor: 5.858

10.  Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload.

Authors:  Norifumi Takeda; Ichiro Manabe; Yuichi Uchino; Kosei Eguchi; Sahohime Matsumoto; Satoshi Nishimura; Takayuki Shindo; Motoaki Sano; Kinya Otsu; Paige Snider; Simon J Conway; Ryozo Nagai
Journal:  J Clin Invest       Date:  2009-12-21       Impact factor: 14.808

View more
  2 in total

1.  Breviscapine attenuatted contrast medium-induced nephropathy via PKC/Akt/MAPK signalling in diabetic mice.

Authors:  Wenbin Jiang; Zhengwei Li; Wei Zhao; Hao Chen; Youyang Wu; Yi Wang; Zhida Shen; Jialin He; Shengyu Chen; Jiefang Zhang; Guosheng Fu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

2.  Fn14 is regulated via the RhoA pathway and mediates nuclear factor-kappaB activation by Angiotensin II.

Authors:  Zhengwei Li; Zhida Shen; Lailing Du; Jialin He; Shengyu Chen; Jiefang Zhang; Yi Luan; Guosheng Fu
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.